Soligenix (NASDAQ:SNGX – Get Free Report) released its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.02, Zacks reports.
Soligenix Trading Down 4.9%
Soligenix stock opened at $0.29 on Friday. The firm has a 50-day moving average price of $1.10 and a 200-day moving average price of $1.28. The firm has a market capitalization of $3.02 million, a PE ratio of -0.08 and a beta of 1.31. Soligenix has a 12-month low of $0.29 and a 12-month high of $6.23.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Soligenix presently has a consensus rating of “Hold” and a consensus price target of $6.00.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in SNGX. Armistice Capital LLC purchased a new position in Soligenix in the 3rd quarter worth about $821,000. Two Sigma Investments LP purchased a new position in Soligenix in the 3rd quarter worth about $102,000. Virtu Financial LLC purchased a new position in Soligenix in the 3rd quarter worth about $59,000. Banco BTG Pactual S.A. purchased a new position in Soligenix in the 3rd quarter worth about $54,000. Finally, Jane Street Group LLC purchased a new position in Soligenix in the 4th quarter worth about $51,000. Hedge funds and other institutional investors own 3.60% of the company’s stock.
About Soligenix
Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.
The company’s pipeline is organized into two core divisions.
Recommended Stories
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.
